Literature DB >> 19500472

Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats.

Yun Sil Chang1, Wonil Oh, Soo Jin Choi, Dong Kyung Sung, Soo Yoon Kim, Eun Yang Choi, Saem Kang, Hye Jin Jin, Yoon Sun Yang, Won Soon Park.   

Abstract

Recent evidence suggests mesenchymal stem cells (MSCs) can downmodulate bleomycin-induced lung injury, and umbilical cord blood (UCB) is a promising source for human MSCs. This study examined whether intratracheal or intraperitoneal transplantation of human UCB-derived MSCs can attenuate hyperoxia-induced lung injury in immunocompetent newborn rats. Wild-type Sprague-Dawley rats were randomly exposed to 95% oxygen or air from birth. In the transplantation groups, a single dose of PKH26-labeled human UCB-derived MSCs was administered either intratracheally (2 x 10(6) cells) or intraperitoneally (5 x 10(5) cells) at postnatal day (P) 5. At P14, the harvested lungs were examined for morphometric analyses of alveolarization and TUNEL staining, as well as the myeoloperoxidase activity, the level of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and transforming growth factor (TGF)-beta mRNA, alpha-smooth muscle actin (SMA) protein, and collagen levels. Differentiation of MSCs to the respiratory epithelium was also evaluated both in vitro before transplantation and in vivo after transplantation. Despite one fourth dosage of MSCs, significantly more PKH26-labeled donor cells were recovered with intratracheal administration than with intraperitoneal administration both during normoxia and hyperoxia. The hyperoxia-induced increase in the number of TUNEL-positive cells, myeloperoixdase activity, and the level of IL-6 mRNA were significantly attenuated with both intratracheal and intraperitoneal MSCs transplantation. However, the hyperoxia-induced impaired alveolarization and increased the level of TNF-alpha and TGF-beta mRNA, alpha-SMA protein, and collagen were significantly attenuated only with intratracheal MSCs transplantation. MSCs differentiated into respiratory epithelium in vitro and a few PKH26-positive donor cells were colocalized with pro surfactant protein C in the damaged lungs. In conclusion, intratracheal transplantation of human UCB-derived MSCs is more effective than intraperitoneal transplantation in attenuating the hyperoxia-induced lung injury in neonatal rats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19500472     DOI: 10.3727/096368909X471189

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  85 in total

1.  Evaluation of the cell viability of human Wharton's jelly stem cells for use in cell therapy.

Authors:  Ingrid Garzón; Barbara Pérez-Köhler; Juan Garrido-Gómez; Victor Carriel; Renato Nieto-Aguilar; Miguel Angel Martín-Piedra; Natalio García-Honduvilla; Julia Buján; Antonio Campos; Miguel Alaminos
Journal:  Tissue Eng Part C Methods       Date:  2012-01-26       Impact factor: 3.056

2.  Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art.

Authors:  Arianna Malgieri; Eugenia Kantzari; Maria Patrizia Patrizi; Stefano Gambardella
Journal:  Int J Clin Exp Med       Date:  2010-09-07

3.  Bioreactor for the long-term culture of lung tissue.

Authors:  Thomas H Petersen; Elizabeth A Calle; Maegen B Colehour; Laura E Niklason
Journal:  Cell Transplant       Date:  2010-11-19       Impact factor: 4.064

4.  Stem cells and cell therapies in lung biology and diseases: conference report.

Authors:  Daniel J Weiss; Jason H T Bates; Thomas Gilbert; W Conrad Liles; Carolyn Lutzko; Jay Rajagopal; Darwin Prockop
Journal:  Ann Am Thorac Soc       Date:  2013-10

5.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

6.  Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy.

Authors:  Karen Bieback; Irena Brinkmann
Journal:  World J Stem Cells       Date:  2010-08-26       Impact factor: 5.326

Review 7.  Regenerative pulmonary medicine: potential and promise, pitfalls and challenges.

Authors:  Piero Anversa; Mark A Perrella; Stella Kourembanas; Augustine M K Choi; Joseph Loscalzo
Journal:  Eur J Clin Invest       Date:  2012-03-21       Impact factor: 4.686

Review 8.  Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: a clinical review.

Authors:  Ann A Simones; Daniel J Beisang; Angela Panoskaltsis-Mortari; Kari D Roberts
Journal:  Pediatr Res       Date:  2017-10-25       Impact factor: 3.756

Review 9.  Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders.

Authors:  Won Soon Park; So Yoon Ahn; Se In Sung; Jee-Yin Ahn; Yun Sil Chang
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

10.  Nanofiber-expanded human umbilical cord blood-derived CD34+ cell therapy accelerates murine cutaneous wound closure by attenuating pro-inflammatory factors and secreting IL-10.

Authors:  Suman Kanji; Manjusri Das; Reeva Aggarwal; Jingwei Lu; Matthew Joseph; Sujit Basu; Vincent J Pompili; Hiranmoy Das
Journal:  Stem Cell Res       Date:  2013-11-15       Impact factor: 2.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.